{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:35:32Z","timestamp":1794645332611,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["116060"],"award-info":[{"award-number":["116060"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02121-w","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:12:33Z","timestamp":1759158753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vivo validation of novel non-invasive PHP.eB AAVs as a potential therapeutic approach for alpha-synucleinopathies"],"prefix":"10.1186","volume":"13","author":[{"given":"Maria","family":"Fouka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraklis","family":"Tsakogias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Georgia","family":"Gialinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Stavropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Volbracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"De Muynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik","family":"Moechars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Melki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Tofaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Xilouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2121_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.952161","volume":"10","author":"C Ding","year":"2022","unstructured":"Ding C, Wu Y, Chen X, Chen Y, Wu Z, Lin Z et al (2022) Global, regional, and national burden and attributable risk factors of neurological disorders: the Global burden of disease study 1990\u20132019. Front Public Health 10:952161","journal-title":"Front Public Health"},{"key":"2121_CR2","doi-asserted-by":"crossref","unstructured":"Koros C, Simitsi A, Stefanis L. Chapter Eight - Genetics of Parkinson\u2019s Disease: Genotype\u2013Phenotype Correlations. In: Bhatia KP, Chaudhuri KR, Stamelou M, editors. International Review of Neurobiology [Internet]. Academic Press; 2017 [cited 2024 Dec 11]. p. 197\u2013231. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0074774217300090","DOI":"10.1016\/bs.irn.2017.01.009"},{"key":"2121_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839\u2013840","journal-title":"Nature"},{"key":"2121_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211","journal-title":"Neurobiol Aging"},{"key":"2121_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38\u201348","journal-title":"Nat Rev Neurosci"},{"key":"2121_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","volume":"92","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A et al (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92:329\u2013337","journal-title":"Neurology"},{"key":"2121_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3390\/biom14080949","volume":"14","author":"AM Caramiello","year":"2024","unstructured":"Caramiello AM, Pirota V (2024) Novel therapeutic horizons: SNCA targeting in Parkinson\u2019s disease. Biomolecules 14:949","journal-title":"Biomolecules"},{"key":"2121_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2010.115","volume":"18","author":"OS Gorbatyuk","year":"2010","unstructured":"Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, Sullivan LF et al (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18:1450\u20131457","journal-title":"Mol Ther"},{"key":"2121_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00036\/full","author":"MJ Benskey","year":"2018","unstructured":"Benskey MJ, Sellnow RC, Sandoval IM, Sortwell CE, Lipton JW, Manfredsson FP (2018) Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity. Front Mol Neurosci [Internet]. https:\/\/doi.org\/10.3389\/fnmol.2018.00036\/full","journal-title":"Front Mol Neurosci [Internet]"},{"key":"2121_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00012\/full","author":"TJ Collier","year":"2016","unstructured":"Collier TJ, Redmond DE, Steece-Collier K, Lipton JW, Manfredsson FP (2016) Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology evidence from non-human primates. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2016.00012\/full","journal-title":"Front Neurosci"},{"key":"2121_CR11","doi-asserted-by":"publisher","first-page":"117906951878671","DOI":"10.1177\/1179069518786715","volume":"12","author":"A Dagher","year":"2018","unstructured":"Dagher A, Zeighami Y (2018) Testing the protein propagation hypothesis of Parkinson disease. J Exp Neurosci 12:1179069518786715","journal-title":"J Exp Neurosci"},{"key":"2121_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14802\/jmd.19046","volume":"12","author":"HK Chung","year":"2019","unstructured":"Chung HK, Ho H-A, P\u00e9rez-Acu\u00f1a D, Lee S-J (2019) Modeling \u03b1-Synuclein propagation with preformed fibril injections. J Move Disord 12:139\u2013151","journal-title":"J Move Disord"},{"key":"2121_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41598-022-04780-4","volume":"12","author":"S Awa","year":"2022","unstructured":"Awa S, Suzuki G, Masuda-Suzukake M, Nonaka T, Saito M, Hasegawa M (2022) Phosphorylation of endogenous \u03b1-synuclein induced by extracellular seeds initiates at the pre-synaptic region and spreads to the cell body. Sci Rep 12:1163","journal-title":"Sci Rep"},{"key":"2121_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-015-1485-1","volume":"131","author":"T Uchihara","year":"2016","unstructured":"Uchihara T, Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131:49\u201373","journal-title":"Acta Neuropathol"},{"key":"2121_CR15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Luk KC, Lee VM-Y (2014) Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 9:2135\u20132146","journal-title":"Nat Protoc"},{"key":"2121_CR16","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1038\/s41598-020-61757-x","volume":"10","author":"J Courte","year":"2020","unstructured":"Courte J, Bousset L, Boxberg YV, Villard C, Melki R, Peyrin J-M (2020) The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding. Sci Rep 10:4895","journal-title":"Sci Rep"},{"key":"2121_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fnins.2018.00621","volume":"12","author":"MF Duffy","year":"2018","unstructured":"Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Fischer DL, Stoll AC et al (2018) Quality over quantity: advantages of using Alpha-Synuclein preformed fibril triggered synucleinopathy to model idiopathic Parkinson\u2019s disease. Front Neurosci 12:621","journal-title":"Front Neurosci"},{"key":"2121_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G (2024) Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther 9:78","journal-title":"Signal Transduct Target Ther"},{"key":"2121_CR19","first-page":"73","volume":"27","author":"R Song","year":"2022","unstructured":"Song R, Pekrun K, Khan TA, Zhang F, Pa\u015fca SP, Kay MA (2022) Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model. Mol Ther 27:73\u201388","journal-title":"Mol Ther"},{"key":"2121_CR20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu W-L et al (2017) Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20:1172\u20131179","journal-title":"Nat Neurosci"},{"key":"2121_CR21","first-page":"55994","volume":"126","author":"MS Grames","year":"2017","unstructured":"Grames MS, Jackson KL, Dayton RD, Stanford JA, Klein RL (2017) Methods and tips for intravenous administration of adeno-associated virus to rats and evaluation of central nervous system transduction. J Vis Exp 126:55994","journal-title":"J Vis Exp"},{"key":"2121_CR22","doi-asserted-by":"publisher","first-page":"eabn4395","DOI":"10.1126\/scisignal.abn4395","volume":"15","author":"A Stavropoulos","year":"2022","unstructured":"Stavropoulos A, Divolis G, Manioudaki M, Gavriil A, Kloukina I, Perrea DN et al (2022) Coordinated activation of TGF-\u03b2 and BMP pathways promotes autophagy and limits liver injury after acetaminophen intoxication. Sci Signal 15:eabn4395","journal-title":"Sci Signal"},{"key":"2121_CR23","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/ncomms3575","volume":"4","author":"L Bousset","year":"2013","unstructured":"Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B et al (2013) Structural and functional characterization of two alpha-synuclein strains. Nat Commun 4:2575","journal-title":"Nat Commun"},{"key":"2121_CR24","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1111\/j.1742-4658.2005.04776.x","volume":"272","author":"M Ghee","year":"2005","unstructured":"Ghee M, Melki R, Michot N, Mallet J (2005) PA700, the regulatory complex of the 26S proteasome, interferes with \u03b1-synuclein assembly. FEBS J 272:4023\u20134033","journal-title":"FEBS J"},{"key":"2121_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"W Peelaerts","year":"2015","unstructured":"Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M et al (2015) \u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522:340\u2013344","journal-title":"Nature"},{"key":"2121_CR26","unstructured":"Paxinos and Franklin\u2019s the Mouse Brain in Stereotaxic Coordinates [Internet]. 2019 [cited 2024 Dec 11]. Available from: https:\/\/shop.elsevier.com\/books\/paxinos-and-franklins-the-mouse-brain-in-stereotaxic-coordinates\/paxinos\/978-0-12-816157-9"},{"key":"2121_CR27","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","volume":"24","author":"SM Fleming","year":"2004","unstructured":"Fleming SM, Salcedo J, Fernagut P-O, Rockenstein E, Masliah E, Levine MS et al (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human \u03b1-synuclein. J Neurosci 24:9434\u20139440","journal-title":"J Neurosci"},{"key":"2121_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/hmg\/ddr521","volume":"21","author":"M Xilouri","year":"2012","unstructured":"Xilouri M, Kyratzi E, Pitychoutis PM, Papadopoulou-Daifoti Z, Perier C, Vila M et al (2012) Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Hum Mol Genet 21:874\u2013889","journal-title":"Hum Mol Genet"},{"key":"2121_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VMY (2012) Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J Exp Med 209:975\u2013986","journal-title":"J Exp Med"},{"key":"2121_CR30","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739\u201329752","journal-title":"J Biol Chem"},{"key":"2121_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip CW, Klaus L-C, Karikari AA, Visanji NP, Brotchie JM, Lang AE et al (2017) AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol Commun 5:11","journal-title":"Acta Neuropathol Commun"},{"key":"2121_CR32","doi-asserted-by":"publisher","first-page":"1051559","DOI":"10.3389\/fneur.2022.1051559","volume":"13","author":"BS Hollidge","year":"2022","unstructured":"Hollidge BS, Carroll HB, Qian R, Fuller ML, Giles AR, Mercer AC et al (2022) Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. Front Neurol 13:1051559","journal-title":"Front Neurol"},{"key":"2121_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","volume":"30","author":"B Nieuwenhuis","year":"2023","unstructured":"Nieuwenhuis B, Laperrousaz E, Tribble JR, Verhaagen J, Fawcett JW, Martin KR et al (2023) Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters. Gene Ther 30:503\u2013519","journal-title":"Gene Ther"},{"key":"2121_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omtm.2023.05.013","volume":"29","author":"S Chai","year":"2023","unstructured":"Chai S, Wakefield L, Norgard M, Li B, Enicks D, Marks DL et al (2023) Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors. Mol Ther Methods Clin Dev 29:504\u2013512","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2121_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/biom10030391","volume":"10","author":"M Teil","year":"2020","unstructured":"Teil M, Arotcarena M-L, Faggiani E, Laferriere F, Bezard E, Dehay B (2020) Targeting \u03b1-synuclein for PD therapeutics: a pursuit on all fronts. Biomolecules 10:391","journal-title":"Biomolecules"},{"key":"2121_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","volume":"11","author":"MJ Benskey","year":"2018","unstructured":"Benskey MJ, Sellnow RC, Sandoval IM, Sortwell CE, Lipton JW, Manfredsson FP (2018) Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity. Front Mol Neurosci 11:36","journal-title":"Front Mol Neurosci"},{"key":"2121_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-3-19","volume":"3","author":"J Lewis","year":"2008","unstructured":"Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S et al (2008) In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 3:19","journal-title":"Mol Neurodegener"},{"key":"2121_CR38","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1172\/JCI64502","volume":"125","author":"AD Zharikov","year":"2015","unstructured":"Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V et al (2015) shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model. J Clin Invest 125:2721\u20132735","journal-title":"J Clin Invest"},{"key":"2121_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","volume":"198","author":"MK Sapru","year":"2006","unstructured":"Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198:382\u2013390","journal-title":"Exp Neurol"},{"key":"2121_CR40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","volume":"341","author":"H Hayashita-Kinoh","year":"2006","unstructured":"Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H (2006) Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson\u2019s disease rat model. Biochem Biophys Res Commun 341:1088\u20131095","journal-title":"Biochem Biophys Res Commun"},{"key":"2121_CR41","doi-asserted-by":"publisher","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","volume":"285","author":"E Doxakis","year":"2010","unstructured":"Doxakis E (2010) Post-transcriptional regulation of \u03b1-Synuclein expression by mir-7 and mir-153. J Biol Chem 285:12726\u201312734","journal-title":"J Biol Chem"},{"key":"2121_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A (2022) Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front Neurol 13:852003","journal-title":"Front Neurol"},{"key":"2121_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-024-01766-3","volume":"12","author":"T Sano","year":"2024","unstructured":"Sano T, Nagata T, Ebihara S, Yoshida-Tanaka K, Nakamura A, Sasaki A et al (2024) Effects of local reduction of endogenous \u03b1-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice. Acta Neuropathol Commun 12:75","journal-title":"Acta Neuropathol Commun"},{"key":"2121_CR44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1535-7163.MCT-19-0360","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen SN, Lock JL, Schoderboeck L, Abraham WC, Hughes SM (2020) CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain. Mol Ther 19:447\u2013458","journal-title":"Mol Ther"},{"key":"2121_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41434-021-00244-y","volume":"29","author":"D Chatterjee","year":"2022","unstructured":"Chatterjee D, Marmion DJ, McBride JL, Manfredsson FP, Butler D, Messer A et al (2022) Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther 29:390\u2013397","journal-title":"Gene Ther"},{"key":"2121_CR46","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M et al (2017) AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol Ther 25:2727\u20132742","journal-title":"Mol Ther"},{"key":"2121_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/genes14020505","author":"KK Chadman","year":"2023","unstructured":"Chadman KK, Adayev T, Udayan A, Ahmed R, Dai C-L, Goodman JH et al (2023) Efficient delivery of FMR1 across the blood brain barrier using AAVphp construct in adult FMR1 KO mice suggests the feasibility of gene therapy for fragile X syndrome. Genes. https:\/\/doi.org\/10.3390\/genes14020505","journal-title":"Genes"},{"key":"2121_CR48","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mds.29897","volume":"39","author":"J Burr\u00e9","year":"2024","unstructured":"Burr\u00e9 J, Edwards RH, Halliday G, Lang AE, Lashuel HA, Melki R et al (2024) Research priorities on the role of \u03b1-synuclein in Parkinson\u2019s disease pathogenesis. Mov Disord 39:1663\u20131678","journal-title":"Mov Disord"},{"key":"2121_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/NEN.0b013e3186fc995","volume":"67","author":"EA Waxman","year":"2008","unstructured":"Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67:402\u2013416","journal-title":"J Neuropathol Exp Neurol"},{"key":"2121_CR50","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41531-022-00388-7","volume":"8","author":"HA Lashuel","year":"2022","unstructured":"Lashuel HA, Mahul-Mellier A-L, Novello S, Hegde RN, Jasiqi Y, Altay MF et al (2022) Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. NPJ Parkinsons Dis 8:136","journal-title":"NPJ Parkinsons Dis"},{"key":"2121_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ana.10846","volume":"55","author":"M Farrer","year":"2004","unstructured":"Farrer M, Kachergus J, Forno L, Lincoln S, Wang D-S, Hulihan M et al (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174\u2013179","journal-title":"Ann Neurol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02121-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:03:27Z","timestamp":1759161807000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02121-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2121"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02121-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was approved by the Ethical Committee for Use of Laboratory Animals of the Biomedical Research Foundation Academy of Athens (License No. 478434) and in accordance with the ARRIVE guidelines and the EU Directive 2010\/63\/EU for animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}